Related Experiment Video
Updated: Aug 27, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy
1Parker H. Petit Institute for Bioengineering and Bioscience (J.K., S.N.T.), George W. Woodruff School of Mechanical Engineering (J.K., S.N.T.), and Wallace H. Coulter Department of Biomedical Engineering (S.N.T.), Georgia Institute of Technology, Atlanta, Georgia; Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia (S.N.T.); and Division of Biological Science and Technology, Yonsei University, Wonju, South Korea (J.K.).
Abstract:
Despite nearly 30 years of development and recent highlights of nitric oxide (NO) donors and NO delivery systems in anticancer therapy, the limited understanding of exogenous NO's effects on the immune system has prevented their advancement into clinical use. In particular, the effects of exogenously delivered NO differing from that of endogenous NO has obscured how the potential and functions of NO in anticancer therapy may be estimated and exploited despite the accumulating evidence of NO's cancer therapy-potentiating effects on the immune system. After introducing their fundamentals and characteristics, this review discusses the current mechanistic understanding of NO donors and delivery systems in modulating the immunogenicity of cancer cells as well as the differentiation and functions of innate and adaptive immune cells. Lastly, the potential for the complex modulatory effects of NO with the immune system to be leveraged for therapeutic applications is discussed in the context of recent advancements in the implementation of NO delivery systems for anticancer immunotherapy applications. SIGNIFICANCE STATEMENT: Despite a 30-year history and recent highlights of nitric oxide (NO) donors and delivery systems as anticancer therapeutics, their clinical translation has been limited. Increasing evidence of the complex interactions between NO and the immune system has revealed both the potential and hurdles in their clinical translation. This review summarizes the effects of exogenous NO on cancer and immune cells in vitro and elaborates these effects in the context of recent reports exploiting NO delivery systems in vivo in cancer therapy applications.
Insights
Nitric oxide (NO) donors show promise in cancer therapy by modulating immune responses. Further research into exogenous NO
Area of Science:
- Immunology
- Oncology
- Biomedical Engineering
Background:
- Nitric oxide (NO) has demonstrated anticancer properties, but its clinical translation is hindered by incomplete understanding of its immune effects.
- Exogenous NO's distinct actions from endogenous NO complicate therapeutic strategy development.
- Despite decades of research, the precise mechanisms of NO in cancer immunotherapy remain to be fully elucidated.
Purpose of the Study:
- To review the current understanding of nitric oxide (NO) donors and delivery systems in modulating cancer immunogenicity and immune cell function.
- To explore the complex interplay between exogenous NO and the immune system in the context of anticancer therapy.
- To discuss the therapeutic potential of NO delivery systems for advancing anticancer immunotherapy.
Main Methods:
- Review of existing literature on NO donors and delivery systems in cancer therapy.
- Analysis of mechanistic studies on NO's effects on cancer cells and immune cells (in vitro).
- Synthesis of recent in vivo findings on NO delivery systems for anticancer immunotherapy.
Main Results:
- NO donors and delivery systems can modulate cancer cell immunogenicity.
- Exogenous NO influences the differentiation and function of innate and adaptive immune cells.
- Recent advancements show potential for NO delivery systems in enhancing anticancer immunotherapy.
Conclusions:
- Understanding exogenous NO's immunomodulatory effects is crucial for clinical translation.
- NO delivery systems offer a promising platform for developing novel anticancer immunotherapies.
- Further research is needed to fully harness the therapeutic potential of NO in cancer treatment.
Related Concept Videos
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Nitric Oxide Signaling Pathway
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

